In addition, another study reported increased FAS mRNA expression and high glucose levels in people with NAFLD [41], so our current results are consistent with previously mentioned publications showing dysregulation of hepatic lipogenesis in NAFLD [42,43]. The gene discussed is FAS; the disease is metabolic dysfunction-associated steatotic liver disease.